Activity Decline for CROs, but the Futures Bright
The number of clinical trials started by leading contract research organisations (CROs) dropped by 50% between 2011 and 2013, according to new research from global pharmaceutical analyst firm Datamonitor Healthcare.
The size of trials handled by CROs also showed a steep decline over the last year, with a 31% reduction in the overall size of the studies carried out.
The results appear to reflect the pharmaceutical industry’s change in emphasis, with drug developers attempting to streamline their pipelines away from more speculative early-stage candidates. The focus is turning to a smaller number of later-stage drug candidates in order to maximise return on investment.
In 2013 CROs tackled 24 later-stage studies of which nine were Phase II and two were Phase I/II, with 11 in Phase III and two in Phase IV. The therapeutic sectors giving the most work to CROs last year were respiratory and dermatology (eight trials), followed by oncology (seven).
Jo Shorthouse, outsourcing editor at Datamonitor Healthcare said: “The pharmaceutical industry is trying to do more with less, and this being a prime example. CROs may be doing fewer trials, but the work they are doing has more depth to it, is more meaningful and more likely to result in effective therapies.
“What we’re seeing is a shift from CROs being little more than hired tradesmen with no true connection to their customers, to an increasingly trusted and closely bound partner. They are now being offered a consultative seat at the table when decisions are being made.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance